Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValiRxLSE:VAL PB Ratio is 0.36 as of Jul. 15, 2026, which is 1700% above its 10-year median of 0.02. The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, ValiRx ranks better than 96.5% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), ValiRx's share price is £0.00145. ValiRx's Book Value per Share for the quarter that ended in Dec. 2025 was £0.00. Hence, ValiRx's PB Ratio of today is 0.36.
Warning Sign:
ValiRx PLC stock PB Ratio (=0.36) is close to 5-year high of 0.36.
The historical rank and industry rank for ValiRx's PB Ratio or its related term are showing as below:
LSE:VAL'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.8
Current: 0.36
During the past 13 years, ValiRx's highest PB Ratio was 0.80. The lowest was 0.01. And the median was 0.02.
LSE:VAL's PB Ratio is ranked better than 96.5% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs LSE:VAL: 0.36
During the past 12 months, ValiRx's average Book Value Per Share Growth Rate was -66.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -55.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -43.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -52.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ValiRx was -20.40% per year. The lowest was -64.40% per year. And the median was -45.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ValiRx PB Ratio Related Terms
ValiRx PB Ratio Historical Data
* Premium members only.
The historical data trend for ValiRx's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ValiRx's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ValiRx PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ValiRx's PB Ratio distribution charts can be found below:
* The bar in red indicates where ValiRx's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ValiRx's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ValiRx (LSE:VAL) has a PB Ratio of 0.36 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ValiRx and its competitors. This is 1700% above median its historical median of 0.02. Over the past decade, ValiRx's PB Ratio has ranged from 0.01 to 0.80. According to the industry distribution chart, ValiRx ranks #43 out of 1228 companies in the Biotechnology industry, placing it in the top 3.5%.
Is ValiRx's PB Ratio too high?
ValiRx's current PB Ratio of 0.36 is 1700% above median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.80. The Biotechnology industry median PB Ratio is 2.90. ValiRx's value of 0.36 is 87.6% below this industry median. Based on the distribution chart, ValiRx ranks #43 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does ValiRx's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ValiRx ranks #43 out of 1228 companies for PB Ratio. This places ValiRx in the top 4% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.90. ValiRx's value of 0.36 is 87.6% below this benchmark. Historically, ValiRx's own PB Ratio has ranged from 0.01 to 0.80 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 2.90, ValiRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ValiRx's current PB Ratio of 0.36 is 87.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ValiRx and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ValiRx's current PB Ratio is 0.36, which is 1700% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ValiRx stock overvalued right now?
ValiRx (LSE:VAL) has a current PB Ratio of 0.36. The current PB Ratio is 0.36, which is 1700% above median its 10-year median of 0.02 and 87.6% below the Biotechnology industry median of 2.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ValiRx (LSE:VAL), the current PB Ratio is 0.36 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VAL has been successfully added to your 
